Navigation Links
Monogram Biosciences to Present at the JMP Securities Healthcare Conference
Date:10/10/2007

SOUTH SAN FRANCISCO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that Alfred G. Merriweather, Senior Vice President and Chief Financial Officer, is scheduled to present a corporate overview at the JMP Securities Healthcare Conference on Tuesday, November 13, 2007 at 11:00 a.m. (Eastern Time) at the Four Seasons Hotel in Boston, Massachusetts.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts: Alfred G. Merriweather

Chief Financial Officer

Tel: 650 624-4576

amerriweather@monogrambio.com

Jeremiah Hall

Feinstein Kean Healthcare<
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... 2011 The Jackson Laboratory (JAX), Sackler School of Graduate ... have unveiled a new mammalian genetics track for Ph.D. students. ... both JAX and Tufts. Combining the faculty and resources of ... disease, and the faculty and resources at JAX, with its ...
... EAST BRUNSWICK, N.J., Jan. 7, 2011 Savient Pharmaceuticals, Inc. ... its business activities related to the U.S. launch and commercialization ... the treatment of chronic gout in adult patients refractory to ... track for the promotional launch of KRYSTEXXA in the first ...
... Biopharma, a biopharmaceutical company developing novel and biosuperior ... that the company has entered into a multi-year ... commercialization of novel peptide-based therapeutics. Under ... receive an upfront payment of an undisclosed amount, ...
Cached Biology Technology:The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3Savient Pharmaceuticals Provides Business Update 2Savient Pharmaceuticals Provides Business Update 3Savient Pharmaceuticals Provides Business Update 4Savient Pharmaceuticals Provides Business Update 5Savient Pharmaceuticals Provides Business Update 6Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics 2
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... at the University of British Columbia have been able ... much touted antioxidant benefits, tracing valuable compounds to the ... Prof. David Kitts found that the prevailing antioxidants present ... green beans being browned under high temperatures. ...
... PORTLAND, Ore. February 1, 2011. Fact: The ... temperature of the nest: warm nests produce females, cooler nests, ... for about 220 million years, scientists now report that almost ... working to understand how global warming may affect turtle reproduction. ...
... dementia is caused by a breakdown of nerve cells ... (fronto-temporal lobe), which leads to, among other symptoms, a ... forms of frontotemporal dementia is a genetically determined reduction ... Anja Capell and Prof. Christian Haass have now shown ...
Cached Biology News:Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists 2Turtle populations affected by climate, habitat loss and overexploitation 2Malaria medication may help against 1 type of frontotemporal dementia 2
... a novel disposable spin filtration device especially ... lysates in plasmid purification procedures. , ... spin filtration device especially designed to aid ... purification procedures. The neutralized lysate is centrifuged ...
... any standard fixed-angle microcentrifuge rotor at ... centrifuge tube filters consist of a ... tube. They filter by centrifugation for ... preparation, removal of cells from media ...
... in any standard fixed-angle microcentrifuge rotor ... g.,Spin- centrifuge tube filters consist of ... centrifuge tube. They filter by centrifugation ... sample preparation, removal of cells from ...
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Biology Products: